Verdict On First Drug To Avert HIV Infection Deferred by FDA

by Nancy Needhima on  June 11, 2012 at 2:29 PM AIDS/HIV News
RSS Email Print This Page Comment bookmark
Font : A-A+

A decision on whether to approve Truvada as the first pill that prevents HIV infection is postponed until mid-September by US health regulators.
Verdict On First Drug To Avert HIV Infection Deferred by FDA
Verdict On First Drug To Avert HIV Infection Deferred by FDA

Drug maker Gilead Sciences said on Friday that the Food and Drug Administration (FDA) would take an additional three months to review its drug application, after the California Company submitted additional materials to the agency earlier this month.

In May, a panel of experts recommended approval of the daily pill for healthy people at high risk of contracting HIV, the Daily Express reported.

The group's vote is non-binding, but the FDA often follows its advice.

Gilead said that it had submitted updated details on its safety materials for patients and doctors using Truvada.

The FDA typically extends its reviews after receiving such information.

Source: ANI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive